CHRS
CHRS clinical trials: Coherus Oncology, Inc.
Every trial on ClinicalTrials.gov where Coherus Oncology, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 29
- Trials linked
- 19
- As lead sponsor
- 10
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CHRS on the catalyst calendar · CHRS registry changes
- Primary completion Aug 2028Sponsor estimatePhase 1/Phase 2NCT07945821A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid TumorsCoherus Oncology, Inc. · Solid TumorRecruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2025ActualPhase 2NCT05359861Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaCoherus Oncology, Inc. · Hepatocellular CarcinomaTerminatedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026Sponsor estimatePhase 1NCT05635643Study of CHS-114 in Participants With Advanced Solid TumorsCoherus Oncology, Inc. · Advanced Solid TumorActive, not recruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 4NCT06457503A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal CancerCoherus Oncology, Inc. · Nasopharyngeal Cancer RecurrentRecruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT06679985A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or...Coherus Oncology, Inc. · Hepatocellular CarcinomaActive, not recruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1NCT06657144A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsCoherus Oncology, Inc. · Metastatic Solid TumorRecruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2025ActualPhase 1NCT04374877Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsCoherus Oncology, Inc. · Advanced Solid TumorCompletedCHRSLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2024ActualPhase 1NCT05757492Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsCoherus Oncology, Inc. · Advanced Solid TumorTerminatedCHRSLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2023ActualPhase 2NCT05177770Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate CancerCoherus Oncology, Inc. · Metastatic Castration-resistant Prostate CancerTerminatedCHRSLeadRCUSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2028Sponsor estimatePhase 1NCT06389526A Study of CHS-1000 in Participants With Advanced or Metastatic Solid TumorsCoherus Oncology, Inc. · Advanced or Metastatic Solid TumorsNot yet recruitingCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2023ActualPhase 1NCT04336098Study of SRF617 in Patients With Advanced Solid TumorsCoherus Oncology, Inc. · Advanced Solid TumorCompletedCHRSLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2022Sponsor estimateNo phase registeredNCT04662892An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving UdenycaCoherus Oncology, Inc. · Febrile NeutropeniaUnknown statusCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2016ActualPhase 3NCT02489227Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque PsoriasisCoherus Oncology, Inc. · Plaque PsoriasisCompletedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2015ActualPhase 3NCT02134210Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)Coherus Oncology, Inc. · Plaque PsoriasisCompletedCHRSLeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 3NCT02115750Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)Coherus Oncology, Inc. · Rheumatoid ArthritisCompletedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2017ActualPhase 3NCT02486939A Long Term Safety Extension Study (CHS-0214-05)Coherus Oncology, Inc. · Rheumatoid ArthritisCompletedCHRSLeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2016ActualPhase 1NCT02650973Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With NeulastaCoherus Oncology, Inc. · HealthyCompletedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 1NCT02418104Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®Coherus Oncology, Inc. · Immunity, HumoralCompletedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 1NCT02385851Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)Coherus Oncology, Inc. · BioequivalenceCompletedCHRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 29, 2027Sponsor estimatePhase 1/Phase 2NCT06975293STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected...STORM Therapeutics LTD · Solid TumorRecruitingCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT07214987PDT For Induction Therapy For Head And Neck CancerMassachusetts General Hospital · Squamous Cell CarcinomaRecruitingCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2029Sponsor estimatePhase 2NCT07423078Window of Opportunity in Preserving Laryngeal Function TrialMatthew Spector · Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)RecruitingCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 2NCT05479045A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer PatientsGeorgetown University · Ovarian Cancer Stage IVWithdrawnCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2029Sponsor estimatePhase 2NCT07140679Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerEmory University · Localized Colon CarcinomaRecruitingCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimatePhase 2NCT07836049PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCCVanderbilt-Ingram Cancer Center · Esophageal Squamous Cell CarcinomaNot yet recruitingCHRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner